Titanovo Logo
Back to Cell Types

PLC/PRF/5Homo sapiens (Human)Cancer cell line

Also known as: PLC-PRF-5, PLC PRF 5, PLC/PRF5, PLCPRF5, PLC-8024, PLC8024, PLC, Alexander cells, Alexander, Primary Liver Carcinoma/Poliomyelitis Research Foundation/5, PCL/PRF/5

🤖 AI SummaryBased on 16 publications

Quick Overview

Hepatocellular carcinoma cell line with known mutations and drug sensitivity profiles.

Detailed Summary

PLC/PRF/5 is a hepatocellular carcinoma (HCC) cell line derived from human liver tissue. It is widely used in research for studying liver cancer mechanisms, drug responses, and genetic alterations. This cell line has been characterized for its mutations in the TERT promoter, which is associated with telomerase activation and cancer progression. Additionally, PLC/PRF/5 has been involved in studies examining copy number variations, gene expression profiles, and chemosensitivity to various anticancer drugs. Its utility in understanding HCC biology and therapeutic strategies is well-documented in multiple studies.

Research Applications

Genomic and transcriptomic profilingDrug sensitivity and chemosensitivity studiesTERT promoter mutation analysisCopy number variation analysisGene expression profiling

Key Characteristics

Mutations in TERT promoterAmplifications in genes like MYC and METSensitivity to various anticancer drugsExpression of liver-specific functions
Generated on 6/15/2025

Basic Information

Database IDCVCL_0485
SpeciesHomo sapiens (Human)
Tissue SourceLiver[UBERON:UBERON_0002107]

Donor Information

Age24
Age CategoryAdult
SexMale

Disease Information

DiseaseAdult hepatocellular carcinoma
LineageLiver
SubtypeHepatocellular Carcinoma
OncoTree CodeHCC

DepMap Information

Source TypeATCC
Source IDACH-001318_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleCDKN2Ap.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G)Homozygous-from parent cell line PLC/PRF/5
MutationSimpleTP53p.Arg249Ser (c.747G>T)Unspecified-PubMed=11799138, CelloPub=CLPUB00439
MutationSimpleTSC2p.Asn1651Ser (c.4952A>G)Homozygous-from parent cell line PLC/PRF/5

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D12S391
15,20
D13S317
11,12
D16S539
13
D18S51
17
D19S433
11,13
D1S1656
14
D21S11
30,33.2
D2S1338
19
D2S441
12,14
D3S1358
15
D5S818
12
D6S1043
13,21
D7S820
9,11
D8S1179
13,16
FGA
19.2,25
Penta D
6,10
Penta E
10,16
TH01
7,8
TPOX
8
vWA
15,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Inazawa J.

Hepatology 35:1476-1484(2002).

DOIPubMed

A pharmacogenomic landscape in human liver cancers.";

Hui L.-J.

Cancer Cell 36:179-193.e11(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Gastroenterology 157:760-776(2019).

DOIPubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.

Satoh M., Shimizu N., Kohara A.

R. Soc. Open Sci. 5:172472-172472(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

Cevik D., Yildiz G., Ozturk M.

World J. Gastroenterol. 21:311-317(2015).

DOIPubMedPMC

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

Nat. Commun. 4:2218.1-2218.7(2013).

DOIPubMedPMC

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Xu J.-C.

Hepatology 58:706-717(2013).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.

Svasti J.

J. Biomed. Biotechnol. 2010:437143.1-437143.18(2010).

DOIPubMedPMC

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Yamori T.

Mol. Cancer Ther. 4:399-412(2005).

DOIPubMed

Human hepatoma cell lines.";

Alexander J.J.

(In book chapter) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo; Japan (1987).

DOI

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Ohashi R., Namba M.

Tissue Cult. Res. Commun. 16:173-178(1997).

DOI

Establishment of a continuously growing cell line from primary carcinoma of the liver.

Alexander J.J., Bey E.M., Geddes E.W., Lecatsas G.

S. Afr. Med. J. 50:2124-2128(1976).

PubMed

Adaptation of cells derived from human malignant tumours to growth in vitro.

Alexander J.J., Bey E.M., Whitcutt J.M., Gear J.H.S.

S. Afr. J. Med. Sci. 41:89-98(1976).

PubMed

Hepatitis B surface antigen produced by a human hepatoma cell line.";

MacNab G.M., Alexander J.J., Lecatsas G., Bey E.M., Urbanowicz J.M.

Br. J. Cancer 34:509-515(1976).

DOIPubMedPMC

Propagation of adenovirus types 40 and 41 in the PLC/PRF/5 primary liver carcinoma cell line.

Grabow W.O.K., Puttergill D.L., Bosch A.

J. Virol. Methods 37:201-207(1992).

DOIPubMed

Proto-oncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5.

Kumagai N., Tsuchimoto K., Tsuchiya M.

Keio J. Med. 40:139-145(1991).

DOIPubMed

Hepatitis B virus gene expression in two cell lines, one derived from a natural human infection, the other experimentally infected in vitro.

Aspinall S., Alexander J.J.

S. Afr. Med. J. 68:751-754(1985).

PubMed

Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.

Revillard J.-P.

Eur. J. Biochem. 165:699-704(1987).

DOIPubMed

Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma.

Tsuda H., Hirohashi S., Shimosato Y., Ino Y., Yoshida T., Terada M.

Jpn. J. Cancer Res. 80:196-199(1989).

DOIPubMedPMC

The PLC/PRF/5 human hepatoma cell line. I. Reevaluation of the karyotype.

Pinto M.R., Bey E.M., Bernstein R.

Cancer Genet. Cytogenet. 18:11-18(1985).

DOIPubMed

The PLC/PRF/5 human hepatoma cell line. II. Chromosomal assignment of hepatitis B virus integration sites.

Bernstein R.

Cancer Genet. Cytogenet. 18:19-26(1985).

DOIPubMed

Comparative expression of hepatitis B virus antigens in several cell model systems.

Aspinall S., Alexander J.J., Bos P.

J. Gen. Virol. 67:2315-2323(1986).

DOIPubMed

Liver cell lines.";

Darlington G.J.

Methods Enzymol. 151:19-38(1987).

DOIPubMed

PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity.

Wong D.C., Purcell R.H.

Infect. Immun. 30:607-611(1980).

DOIPubMedPMC

Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells.

Keong A., Rabson A.R.

Cancer Immunol. Immunother. 15:178-182(1983).

DOIPubMedPMC

Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Knowles B.B., Howe C.C., Aden D.P.

Science 209:497-499(1980).

DOIPubMed

Induction of hepatitis B surface antigen in human hepatoma-derived cell lines.

Oefinger P.E., Bronson D.L., Dreesman G.R.

J. Gen. Virol. 53:105-113(1981).

DOIPubMed

Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.

Koshy R., Maupas P., Muller R., Hofschneider P.H.

J. Gen. Virol. 57:95-102(1981).

DOIPubMed

Chromosomes of human hepatoma cell lines.";

Simon D., Aden D.P., Knowles B.B.

Int. J. Cancer 30:27-33(1982).

DOIPubMed

Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity.

Keong A., Herman J., Rabson A.R.

Cancer Immunol. Immunother. 15:183-187(1983).

DOIPubMedPMC

A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice.

Sattler F.R., Paolucci S., Kreider J.W., Ladda R.L.

Eur. J. Cancer Clin. Oncol. 18:381-389(1982).

DOIPubMed

Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.

Yachi A.

J. Gastroenterol. 29:727-732(1994).

DOIPubMed

HLA expression in hepatocellular carcinoma cell lines.";

Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.

Clin. Exp. Immunol. 97:328-333(1994).

DOIPubMedPMC

Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.

Ponchel F., Yakicier C., Ji J.-W., Ozturk M.

FASEB J. 7:1407-1413(1993).

DOIPubMed

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Harris C.C.

Carcinogenesis 14:987-992(1993).

DOIPubMed

Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.

Kosaka T., Tsuji T., Namba M.

J. Med. Virol. 48:133-140(1996).

DOIPubMed

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

Cell. Immunol. 175:101-110(1997).

DOIPubMed

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

Itoh K.

Cell. Immunol. 177:176-181(1997).

DOIPubMed

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

DOIPubMed

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Fukaya K.-i., Ishioka C., Namba M.

Acta Med. Okayama 51:261-265(1997).

DOIPubMed

Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.

Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.

Oncol. Rep. 6:1267-1271(1999).

DOIPubMed

A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.

Wong N., Lai P.B.-S., Pang E., Leung T.W.-T., Lau J.W.-Y., Johnson P.J.

Hepatology 32:1060-1068(2000).

DOIPubMed

Web Resources

lccl.zucmanlab.comtcpaportal.org